Pulmatrix, Inc., a biopharmaceutical company developing inhaled therapies for serious pulmonary diseases, has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery. The collaboration will leverage Pulmatrix’s iSPERSE platform in an effort to transform promising assets to improve drug delivery and safety profiles. “This collaboration is an important milestone validating the promise of the iSPERSE™ plat...